Metraipolis › archive › dc_f13a57b2fcab
Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of… — Europe PMC PMID:42495454
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42495454
- DOI
- 10.7759/cureus.111322
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T06:49:14.981Z
- SHA-256 of the archived text
b235b7d229680ecffdbab3ab2baa09def500114435122874cfb06056b42d3d6f- Stable URL of this page
https://metraipolis.com/documento/dc_f13a57b2fcab
How to cite
Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of… — Europe PMC PMID:42495454 — Europe PMC (en), https://europepmc.org/article/MED/42495454 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f13a57b2fcab (Metraipolis archive dc_f13a57b2fcab, sha256 b235b7d229680ecffdbab3ab2baa09def500114435122874cfb06056b42d3d6f)
BibTeX
@misc{dcf13a57b2fcab,
title = {Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of… — Europe PMC PMID:42495454},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42495454},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f13a57b2fcab; sha256 b235b7d229680ecffdbab3ab2baa09def500114435122874cfb06056b42d3d6f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42495454. Agents can read the archived copy with the MCP tool read_document.